Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on May 10, 2024. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2024. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. These figures are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the issuance of Q1 2024 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It notes that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is Ocuphire Pharma, Inc. (Ticker: OCUP), as the input metadata incorrectly listed "Opus Genetics, Inc."
- Review Exhibit 99.1 (the Press Release) for actual Q1 2024 financial figures, as they are not included in the 8-K cover text.
- Confirm the reporting period is the quarter ended March 31, 2024.
- Note that the financial data in the press release is "furnished" and not technically "filed" under Section 18 of the Exchange Act.